Oral lichenoid lesions in HIV-HCV-coinfected subjects during antiviral therapy: 2 cases and review of the literature.
Some dental materials and certain drugs may induce epithelial alterations, which clinically resemble oral lichen planus (OLP), on oral mucosa. But these alterations do not have all the clinical and/or the histological features of OLP; these lesions are known as oral lichenoid lesions (OLLs). Some researchers describe the onset and/or the worsening of OLL/OLP after the administration of anti-hepatitis C virus (HCV) therapy. In this article, we describe the development of symptomatic OLLs, as a consequence of anti-HCV therapy (interferon-alpha and ribavirine), in 2 human immunodeficiency virus-HCV-coinfected subjects. An immunological cause related to coinfection and administration of different medications could be responsible for the onset of OLLs. These new cases, together with the previous reports of a possible association between OLP and/or OLL and anti-HCV therapy, highlight the absolute need to monitor carefully the human immunodeficiency virus-HCV-coinfected subjects who are about to start the anti-HCV therapy and to define better the clinical and histopathological criteria to distinguish OLP from OLL.
Giuliani
Michele
M
School of Dentistry, Catholic University, Rome, Italy. michele.giuliani@rm.unicatt.it
Lajolo
Carlo
C
Sartorio
Alessandra
A
Scivetti
Michele
M
Capodiferro
Saverio
S
Tumbarello
Mario
M
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D017676:Lichen Planus, Oral / Q000175:diagnosis / Q000473:pathology; D017512:Lichenoid Eruptions / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D009061:Mouth Mucosa / Q000473:pathology; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin